NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal

Naltrexone as a treatment for relapse prevention

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Bristol-Myers Squibb Pharmaceuticals Ltd (naltrexone)	 Board of Community Health Councils in Wales British National Formulary
Patient/carer groups	 HM Prison Service
Addaction	 National Public Health Service for
ADFAM	Wales
 Alliance (formerly the Methadone Alliance) 	 National Treatment Agency for Substance Misuse (NTA)
 Families Anonymous 	NHS Confederation
Lifeline	 NHS Purchasing and Supplies Agency
 Rehabilitation for Addicted Prisoners Trust (RAPt) 	 NHS Quality Improvement Scotland
Release	Comparator manufacturers
Turning Point	• none
Professional groups	Relevant research groups
Addiction Recovery Foundation	Action on Addiction
 Association of Nurses in Substance 	 Centre for Research on Drugs and
Abuse (ANSA)	Health Behaviour (Imperial College)
British Association for	Department of Addictive Behaviour (St
Psychopharmacology	George's Hospital Medical School)
 Federation of Drug and Alcohol Professionals 	DrugScope
 National Drug Prevention Alliance 	 Independent Drug Monitoring Unit (IDMU)
 National Pharmaceutical Association 	 National Addiction Centre (Institute of
 Pharmaceutical Services Negotiating 	Psychiatry)
Committee	 Society for the Study of Addiction
Royal College of General	, , , , , , , , , , , , , , , , , , , ,
Practitioners	Assessment team
Royal College of Nursing	 West Midlands Health Technology
 Royal College of Physicians of 	Assessment Collaboration
Edinburgh	National Coordinating Centre for Health
Royal College of Physicians	Technology Assessment
Royal Pharmaceutical Society	

National Institute for Health and Clinical Excellence

Consultation on the draft scope for the appraisal of naltrexone as a treatment for relapse prevention

Consultees	Commentators (no right to submit or appeal)
 Substance Misuse Management in	 <u>Associated Guideline Groups</u> National Collaborating Centre for
General Practice (SMMGP) UK Harm Reduction Alliance <u>Others</u> Department of Health East Leeds PCT Great Yarmouth PCT Welsh Assembly Government	Mental Health

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Clinical Excellence Consultation on the draft scope for the appraisal of naltrexone as a treatment for relapse prevention

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government; relevant NHS organisations in England and local health boards in Wales.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and consultee organisations representing patient/carers and professionals can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, the *British National Formulary*, and the British Medical Association.

Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).